share_log

Syndax Pharmaceuticals Received FDA Orphan Drug Designation on Wednesday for axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

Syndax Pharmaceuticals Received FDA Orphan Drug Designation on Wednesday for axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

Syndax製藥公司週三獲得FDA孤兒藥物稱號，用於治療特發性肺纖維化的Aaxatilimab
Benzinga Real-time News ·  2021/04/08 17:23

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=807821

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=807821

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論